NCT04313244已完成3 期
A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged ≥9 to <15 Years in an Endemic Country for Dengue
Takeda8 个研究点 分布在 1 个国家目标入组 614 人开始时间: 2021年5月15日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 614
- 试验地点
- 8
- 主要终点
- Geometric Mean Titers (GMTs) for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, 58
研究概览
简要总结
The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.
详细描述
The vaccine being tested in this study is called Tetravalent Dengue Vaccine (TDV). The study will assess the immunogenicity and safety on the co-administration of 9vHPV vaccine with TDV in healthy participants aged ≥9 to <15 years.
The study will enroll approximately 614 healthy volunteers. Participants will be randomly assigned to one of the two treatment groups-
- Group 1
- Group 2
All participants will receive recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) intramuscular (IM) in combination with Dengue Tetravalent Vaccine (TDV) subcutaneous (SC) injection on Day 1 (Month 0 ) followed by 9vHPV on Day 90 (Month 3) and TDV on Day 180 (Month 6) in Group 1. Participants will receive 9vHPV on Day 1 (Month 0) and Day 180 (Month 6) IM in Group 2.
This multi-center trial will be conducted in Thailand. The overall time to participate in this study is 12 months. Participants will make multiple visits to the clinic, after last dose of study drug for a follow-up assessment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 9 Years 至 14 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs), and the clinical judgment of the investigator.
- •Participants who can comply with trial procedures and are available for the duration of follow-up.
排除标准
- •Has an elevated oral temperature ≥38°C (≥100.4°F) within 3 days of the intended date of vaccination.
- •Participants with contraindications, warnings and/or precautions to vaccination with Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) vaccine as specified within the prescribing information.
- •Has any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease.
- •Known or suspected impairment/alteration of immune function, including:
- •Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0) (use of inhaled, intranasal, or topical corticosteroids is allowed).
- •Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0).
- •Administration of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (Month 0) or planned administration during the trial.
- •Receipt of immunostimulants within 60 days prior to Day 1 (Month 0).
- •Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (Month 0).
- •Human immunodeficiency virus (HIV) infection or HIV-related disease.
- •Hepatitis B virus infection.
- •Hepatitis C virus infection.
- •Genetic immunodeficiency.
- •Abnormalities of splenic or thymic function.
- •Has a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- •Who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this trial or who are planning to receive any vaccine within 28 days of trial vaccine administration.
- •Who have used antipyretics and/or analgesic medications within 24 hours prior to vaccination. The reason for their use (prophylaxis versus treatment) must be documented. Trial entry should be delayed to allow for a full 24 hours to have passed since last use of antipyretics and/or analgesic medications.
- •Previous and planned vaccination (during the trial conduct), against any flavivirus (except Japanese encephalitis [JE]) including dengue, yellow fever (YF) viruses or tick-borne encephalitis.
- •Previous and planned vaccination (during the trial conduct) against HPV.
- •Previous participation in any clinical trial of a dengue or other flavivirus (eg, West Nile [WN] virus) candidate vaccine, except for participants who received placebo in those trials.
- •Has a current or previous infection with a flavivirus such as Zika, YF, JE, WN fever, tick-borne encephalitis or Murray Valley encephalitis.
结局指标
主要结局
Geometric Mean Titers (GMTs) for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, 58
时间窗: Day 210 (Month 7)
GMTs for HPV were measured by immunoglobulin G binding assay (IgGBA) assay. HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58 were the types of HPV analyzed.
次要结局
- Percentage of Participants With Seropositivity for HPV Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 as Measured by Immunoglobulin G Binding Assay (IgGBA)(Day 210 (Month 7))
- Percentage of Participants With Solicited Local Adverse Events for 7 Days Following Vaccination by Severity(Up to 7 days (Day of vaccination + 6 subsequent days) after each vaccination)
- Percentage of Participants With Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes(Day 120 (Month 4))
- GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes(Day 120 (Month 4))
- Percentage of Participants With Any Unsolicited AEs for 28 Days Following Vaccination(Up to 28 days (Day of vaccination + 27 subsequent days) after each vaccination)
- Percentage of Participants With Seropositivity for Each of the 4 Dengue Serotypes(Day 120 (Month 4))
- Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 14 Days Following Vaccination by Severity(Up to 14 days (Day of vaccination + 13 subsequent days) after each vaccination)
- Percentage of Participants With Serious Adverse Events (SAEs)(From first vaccination (Day 1 [Month 0]) through end of study (Day 360 [Month 12]))
研究者
研究点 (8)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy AdultsCOVID-19 PreventionNCT04908722Janssen Vaccines & Prevention B.V.1,609
已完成
3 期
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and AboveRespiratory Syncytial Virus InfectionsNCT05590403GlaxoSmithKline1,544
已完成
3 期
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy AdultsCOVID-19 PreventionNCT05091307Janssen Vaccines & Prevention B.V.861
已完成
3 期
A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 YearsRespiratory Syncytial Virus PreventionNCT05101486Janssen Vaccines & Prevention B.V.755
尚未招募
3 期
Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil.Pneumococcal VaccinesNCT05721456Maria de Lourdes de Sousa Maia, MD2,400